Atheromatous plaque formation and thrombogenesis: Formation, risk factors and therapeutic approaches

European Heart Journal, Supplement

Volumn 3, Issue I, 2001, Pages

  Badimon, Lina ^a,b   Vilahur, G ^a   Sanchez, S ^a   Duran, X ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b DEPT OF ENVIRONMENTAL CHEMISTRY   (Spain)

Author keywords

Atherogenesis; Lipids; Platelets; Thrombosis; Triflusal

Indexed keywords

ANTITHROMBOCYTIC AGENT; CYCLOOXYGENASE 2; PROSTACYCLIN; TRIFLUSAL;

ANGIOCARDIOGRAPHY; ATHEROGENESIS; ATHEROSCLEROTIC PLAQUE; BLOOD CLOTTING; CLINICAL FEATURE; CLINICAL TRIAL; CORONARY ARTERY THROMBOSIS; DISEASE PREDISPOSITION; DRUG MECHANISM; ECHOGRAPHY; ENZYME ACTIVITY; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HUMAN; PRIORITY JOURNAL; REVIEW; RISK FACTOR; THROMBOCYTE ACTIVATION; THROMBOGENESIS; TREATMENT PLANNING;

EID: 0034898476     PISSN: 1520765X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1520-765X(01)90102-6     Document Type: Review

References (84)

1. The pathogenesis of coronary artery disease and the acute coronary syndromes (Part I)
2. The pathogenesis of coronary artery disease and the acute coronary syndromes (Part II)
3. Characterization of the relative thrombogenicity of atherosclerotic plaque components: Implications for consequences of plaque rupture
4. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques
5. Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques. Effects of TFPI on plaque thrombogenicity under flow conditions
6. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque
7. In situ localization of tissue factor in human atherosclerotic plaques by binding of digoxigenin-labeled factors VIIa and X
8. Differential expression of tissue factor protein in directional atherectomy specimens from patients with stable and unstable coronary syndromes
9. Macrophage infiltration in acute coronary syndromes. Implicaticons for plaque rupture
10. Macrophages, smooth muscle cells, and tissue factor in unstable angina. Implications for cell-mediated thrombogenicity in acute coronary syndromes
11. Shed membrane microparticles with procoagulant potential in human atherosclerotic plaques: A role for apoptosis in plaque thrombogenicity
12. Blood-borne tissue factor: Another view of thrombosis
13. A sudden increase in plasma epinephrine levels transiently enhances platelet deposition on severely damaged arterial wall
14. Mechanism of epinephrine-induced platelet aggregation
15. Synergistic effect of epinephrine and shearing on platelet activation
16. Mental stress as a trigger of myocardial ischemia and infarction
17. Circadian variation in the frequency of onset of acute myocardial infarction
18. The pathophysiology of the onset of morning cardiovascular events
19. Increased morning incidence of myocardial infarction in the ISAM Study: Absence with prior beta-adrenergic blockade
20. Smoking-induced coronary vasoconstriction in patients with atherosclerotic coronary artery disease: Evidence for adrenergically mediated alterations in coronary artery tone
21. Platelet survival and the development of coronary artery disease in the young adult: Effects of cigarette smoking, strong family history and medical therapy
22. The influence of acute smoking on leucocytes, platelets and the endothelium
23. Background of the prevention of cardiovascular disease. II. Arteriosclerosis, hypertension, and selected risk factors
24. Impact of smoking on heart attacks, strokes, blood pressure control, drug dose, and quality of life aspects in the International Prospective Primary Prevention Study in Hypertension
25. The relation between abnormal hemostatic function and the progression of coronary disease
26. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris
27. Effects of reducing LDL and increasing HDL with Gemfibrozil in experimental coronary lesion development and thrombotic risk
28. Effects of statins in thrombosis and aortic lesion development in a dyslipemic rabbit model
29. Platelet deposition on eroded vessel wall at stenotic shear rate is inhibited by lipid-lowering treatment with atorvastatin
30. NOSII gene expression correlates with atherosclerotic intimal thickening. Preventive effects of HMG-CoA reductase inhibitors
31. Platelet deposition at high shear rates is enhanced by high plasma cholesterol levels. In vivo study in the rabbit model
32. Hypercholesterolemia and endothelial dysfunction
33. Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction
34. Statins and cardiovascular diseases: The multiple effects of lipid-lowering therapy by statins
35. Hyperhomocysteinemia as a risk factor for arterial and venous disease. A review of evidence and relevance
36. Hyperhomocysteinemia and atherothrombotic disease
37. Plasminogen activator inhibitor-1: A common denominator in cardiovascular disease
38. Concentration of endogenous tPA antigen in coronary artery disease: Relation to thrombotic events, aspirin treatment, hyperlipidemia, and multivessel disease
39. Association of fibrinolytic parameters with early atherosclerosis. The ARIC Study. Atherosclerosis Risk in Communities Study
40. Fibrinogen and cardiovascular disease
41. Coronary vasospasm as a possible cause of myocardial infarction. A conclusion derived from the study of 'preinfarction' angina
42. Ischemia-related lesion characteristics in patients with stable or unstable angina. A study with intracoronary angioscopy and ultrasound
43. Unstable angina. A comparison of angioscopic findings between diabetic and nondiabetic patients
44. Coronary angioscopy in patients with unstable angina pectoris
45. Angioscopic evaluation of coronary-artery thrombi in acute coronary syndromes
46. Angioscopy of culprit coronary lesions in unstable angina pectoris and correlation of clinical presentation with plaque morphology
47. Coronary angioscopic findings in the infarct-related vessel within 1 month of acute myocardial infarction: Natural history and the effect of thrombolysis
48. Percutaneous coronary angioscopy in patients with ischemic heart disease
49. Acute coronary syndromes: Unstable angina and non-Q-wave myocardial infarction
50. Diagnosing and managing unstable angina
51. Coronary plaque disruption
52. Five-year angiographic follow-up of factors associated with progression of coronary artery disease in the Coronary Artery Surgery Study (CASS)
53. Is myocardial revascularisation for tight coronary stenoses always necessary?
54. Sudden death in coronary artery disease: Acute ischemia versus myocardial substrate
55. Pathogenesis of thrombosis
56. Platelet membrane glycoproteins: Functions in cellular interactions
57. Organization of glycoproteins within the platelet plasma membrane
58. Thromboregulation: Multicellular modulation of platelet reactivity in hemostasis and thrombosis
59. Calcium regulation of the platelet membrane glycoprotein Iib-IIIa complex
60. Expression and function of adhesive proteins on the platelet surface
61. New perspectives in cell adhesion: RGD and integrins
62. The amino acid sequence of the a-chain of human fibrinogen
63. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation
64. Thrombin receptor structure and function
65. Serial angiographic assessment of coronary artery obstruction and collateral flow in acute myocardial infarction
66. Effect of intravenous tissue plasminogen activator on infarct size, left ventricular function and survival in patients with acute myocardial infarction
67. Angiographic assessment of the infarct-related residual coronary stenosis after spontaneous or therapeutic thrombolysis
68. Atheroscerotic plaque rupture and thrombosis: Evolving concepts
69. Coronary lesion morphology in acute myocardial infarction: Demonstration of early remodeling after streptokinase treatment
70. Increased thrombin levels during acute myocardial infarction. Relevance for the success of therapy
71. Mechanism of arterial thrombosis in non-parallel strealines: Platelet grow at the apex of stenotic severely injured vessel wall. Experimental study in the pig model
72. Dynamic monitoring of platelet deposition on severely damaged vessel wall in flowing blood. Effects of different stenosis on thrombus growth
73. 2 in reocclusion following coronary thrombolysis with tissue-type plasminogen activator
74. Inhibition of growth of thrombus on fresh mural thrombus: Targeting optimal therapy
75. Dissolution of mural thrombus by specific thrombin inhibition with r-hirudin: Comparison with heparin and aspirin
76. Effects of triflusal and acetylsalicylic acid on platelet aggregation in whole blood of diabetic patients
77. Effect of triflusal and other salicylic acid derivatives on cyclic AMP levels in rat platelets
78. Pharmacokinetics of triflusal and its main metabolite HTB in healthy subjects following a single oral dose
79. Pharmacokinetics of triflusal after single and repeated doses in man
80. In vitro protein binding interaction between a metabolite of triflusal, 2-hydroxy-4-trifluoromethylbenzoic acid and other drugs
81. Triflusal versus acetyl-salicylic acid: A double-blind study for the prophylaxis of deep vein thrombosis after hip surgery
82. Randomized comparative trial of triflusal and aspirin following acute myocardial infarction
83. Incidence of vascular stroke in patients with acute myocardial infarction receiving fibrinolytic treatment
84. Thrombus growth on residual thrombus is inhibited and vascular wall Cox2 upregulated by treatment with Triflusal